Eli Lilly reported better-than-expected Q2 2026 results with revenue up 48% to $22.97 billion, driven by its GLP-1 portfolio including Zepbound and Mounjaro, prompting the company to raise its full-year revenue guidance.
Bank of America spends over $250 million annually covering GLP-1 weight loss drugs for employees, accounting for roughly 13% of its $2 billion healthcare budget, CEO Brian Moynihan told CNBC.
The "proteinmaxxing" trend and GLP-1 weight-loss medications are driving up demand for whey protein, a vital ingredient in infant formula. This has led to a 4.8% increase in UK formula prices, raising concerns about affordability for families and prompting calls for government-imposed price or profit caps.
Despite new GLP-1 drugs and Medicare coverage, most employers aren't covering them for weight loss due to high costs. Many are exploring alternative support methods for employees.
Despite new GLP-1 drugs and Medicare coverage, most employers aren't covering them for weight loss due to high costs. Many are exploring alternative support methods for employees.
The US dairy industry is experiencing a whey protein boom, fueled by GLP-1 weight loss drugs, leading to shortages and price hikes. This shift is transforming cheesemaking, with whey now a valuable co-product rather than waste, and impacting traditional dairy production.
Many insurance plans are dropping coverage for GLP-1 drugs like Zepbound and Wegovy for weight loss, leaving patients like Deborah Finley struggling to afford them. Experts suggest navigating coverage by checking fine print, filing appeals with doctor support, documenting care, seeking discounts, and being cautious with compounded versions.
UPS is investing $48 million in 27 temperature-controlled facilities globally to meet the rising demand for GLP-1 weight-loss drugs and other sensitive medications, ensuring they remain within required temperature ranges for patient use.
A new study suggests GLP-1 drugs, known for weight loss and diabetes treatment, may slow the progression of certain obesity-related cancers. Comparing GLP-1 users to those on DPP-4 inhibitors, researchers found reduced cancer spread in lung, breast, colorectal, and liver cancers.
Four new studies suggest GLP-1 drugs like Wegovy and Mounjaro may improve cancer treatment outcomes. Research indicates lower rates of cancer metastasis and improved survival rates in patients taking these medications.
The rising popularity of GLP-1 weight-loss drugs is driving a surge in demand for hair-care products as users report temporary hair loss. Beauty companies are now innovating and marketing specific treatments to address this growing side effect.
The increasing adoption of GLP-1 weight loss drugs is creating a significant opportunity for the U.S. apparel industry, with analysts predicting a substantial boost in clothing sales and spending as consumers refresh their wardrobes after significant weight loss.
